Global Parkinson’s disease Treatment Market 2020-2026
1
Transilience Market Research | Sales@transiliencemarketresearch.com
Global Parkinson’s Disease Treatment Market 2020 By Drug Class [Carbidopa/Levodopa, CatecholO-methyl transferase (COMT) inhibitors, Dopamine agonists (non-ergoline),Dopamine precursors, Monoamine oxidase B inhibitors (MAO-B inhibitors) and others],By Medical Devices [Deep Brain Stimulation (DBS) Devices, Levodopa Enteral Suspension delivery devices and others], By Patient Care Setting[Clinics, Hospitals and others], By Distribution Channel[Online pharmacies, Retail pharmacies, Hospital pharmacies and others: Global Forecast to 2026 and COVID-19 Impact Outlook Global Parkinson’s Disease Treatment Market is valued at USD 4.54 Billion in 2019 and expected to reach USD 6.97 Billion by 2026 with the CAGR of 6.33 % over the forecast period.
Scope of the report Parkinson's disease is a neurodegenerative disease which affects more than 30 million patients worldwide. Massive progress has been made in the treatment of Parkinson’s disease. Several companies are offering novel therapies and treatments to treat the disease showing promising results in clinical trials. These include deep brain stimulation devices based treatments, stem cell based therapies, gene therapies and target drug delivery with potentially disease-modifying properties. Further growing capital investments such as Parkinson's Foundation’s investment of $4.2 million across 46 research grants to advance Parkinson’s disease research in 2019 will offer several growth opportunities in future. KNOW MORE This report analyses the global market for Parkinson’s Disease Treatment. The report will enable the user to understand and gain insights into the current and forecast market situation. The market is comprehensively analyzed by geography to give complete information on the global scenario. The qualitative and quantitative data provided in this study can help user understand which market segments, regions are expected to grow at higher rates, factors affecting the market and key opportunity areas. The report also includes competitive landscape of key players in the industry along with emerging trends in the market.
Key Players 1. Apotex Inc. 2
2. BIAL Pharm 3. Cipla Inc. 4. Daiichi Sankyo Transilience Market Research | Sales@transiliencemarketresearch.com
5. GlaxoSmithKline Plc. 6. Impax Laboratories Inc. 7. Mylan N.V. 8. Novartis AG 9. Orion Corporation 10. Par Pharmaceutical 11. Salix Pharmaceuticals 12. Teva Pharmaceutical Industries Ltd. 13. Wockhardt Limited 14. others Above mentioned companies were scrutinized to assess competitive landscape of global Parkinson’s Disease Treatment market. Report provides company profiles of each player. Each profile include company product portfolio,business overview, company governance, company financials, business strategies, manufacturing locations and production facilities, company sale, recent developments and strategic collaborations & partnerships, new product launch, company segments, application diversification and company strength and weakness analysis.
Review period: (2016-2026) Historic Period: 2016 to 2019 Forecast Period: 2020 to 2026 Base Year: 2019 Unit: USD Billion This Parkinson’s Disease Treatment market report provides insights on new trade regulations, import export analysis, industry value chain analysis, market size, consumption, production analysis, regional and segment market share, product launches, product pipeline analysis, impact of Covid-19 on supply chain, key regions, untapped markets, patent analysis, product approvals, continuous innovations and developments in the market. REQUEST SAMPLE
Regions
3
North America: U.S., Canada and Rest of North America
Europe: UK, France, Germany, Italy, Spain and Rest of Europe Transilience Market Research | Sales@transiliencemarketresearch.com
Asia Pacific: China, Japan, India, Australia, Southeast Asia and Rest of Asia Pacific
Latin America: Brazil, Mexico, Argentina and Rest of Latin America
Middle East and Africa: Gulf Countries, Israel, Africa and Rest of Middle East and Africa
Region Insights Europe dominates the Global Parkinson’s disease Treatment market. The growth in the region is primarily due to presence of advanced healthcare infrastructure, sophisticated medical facilities, key players and growing prevalence of Parkinson’s disease. The region has more than 1 million people living with Parkinson’s today. Prevalence rate in the 60-69-year-old population is approximately 1.0% whereas in people over 80 its 2.7%. The figure is expected to double by 2030 with ageing population. Asia Pacific was fastest growing market with rising geriatric population in countries like China and Japan. The burden of disease is snowballing in China. It is projected that china will account about half of Parkinson’s disease population in the world by 2030. Significant rise in geriatric population in the country will drive growth in forecast period. It is estimated that country will have more than 26.9% population over 65 years old in 2050.
Global Parkinson’s disease Treatment Market Dynamics Growing geriatric population and prevalence of Parkinson’s disease around the world is driving the growth of Parkinson’s disease Treatment market. According to Parkinson’s foundation worldwide more than 10 million people are living with Parkinson’s disease. Significant surge in geriatric population will drive the growth in forecast period. According to United Nations globally there are 703 million people aged 65 years or more. By 2050 the number is expected to double to 1.5 billion. However, stringent regulatory policies, contradictions over present drug effectiveness and efficacy, adverse side effects are hampering the growth of global market. Ongoing clinical trials, new therapies based on deep brain stimulation will offer significant opportunities in the forecast period. For instance in August 2019 FDA approved Japan based Kyowa Kirin’s Nourianz (istradefylline) tablets to treat Parkinson’s disease in adults.
Market Segmentation
Drug Class o Carbidopa/Levodopa o Catechol-O-methyl transferase (COMT) inhibitors o Dopamine agonists (non-ergoline) o Dopamine precursors o Monoamine oxidase B inhibitors (MAO-B inhibitors) o Others Transilience Market Research | Sales@transiliencemarketresearch.com
4
Medical Devices o Deep Brain Stimulation (DBS) Devices o Levodopa Enteral Suspension delivery devices Patient Care Setting o Clinics o Hospitals Distribution Channel o Online pharmacies o Retail pharmacies o Hospital pharmacies
Report Coverage
An overview of the global Parkinson’s Disease Treatment market
In depth analysis of market dynamics and major factors such as drivers, restraints, opportunities and trends influencing the global market
Global Parkinson’s Disease Treatment market revenue data historic and forecast analysis (2016 to 2026)
Characterization and quantification of the market segments for Parkinson’s Disease Treatment market
Market share analysis of key market participants and their competitive landscape
Important Questions Answered by Global Parkinson’s Disease Treatment Market Report
What is the impact of COVID 19 epidemic on the global Parkinson’s Disease Treatment market?
Which is mostly affected region, country?
Which is the current largest and fastest-growing region?
What is the market size and growth rate of the global Parkinson’s Disease Treatment market?
What are current factors affecting the growth of market?
What are Key trends and opportunity areas?
Within Parkinson’s Disease Treatment market, which segments are fastest growing & emerging strongly? What are the drivers and restraints for each segment? What are vendor competencies by segment?
What are the major strategies adopted by leading market companies?
What are company challenges and essential success factors by market segment?
Transilience Market Research | Sales@transiliencemarketresearch.com
5
How company offerings and supply chain capabilities are shifting to meet emerging market needs?
Global Parkinson’s Disease Treatment Market COVID-19 impact Analysis This report highlights the impact of the Covid-19 pandemic on Global Parkinson’s Disease Treatment Market. By combining data from a range of industry sources, as well as predictive modelling and market trend analysis, we provide an evidence-based set of projections that will allow organisations to plan their strategies more effectively. The report gives in depth analysis of short term and long term impacts of epidemic on the industry. The COVID 19 impact assessment of Global Parkinson’s Disease Treatment Market is divided into following sections: Section1: Pre Lockdown This part of the report looks at how market changed throughout early 2020, as the spread of COVID19 intensified on different geographies. Section2: During Lockdown This part of the report collects data from across the sector to know how people have responded to lockdown. It analyses the impact of the epidemic on the workforce in the industry and disruption in various regions and countries Section3: Post Lockdown This part of the report project what sector recovery could look like and summarises ways in which the business landscape could shift. Get detailed COVID 19 Impact Analysis on Global Parkinson’s Disease Treatment Market Here
6
Transilience Market Research | Sales@transiliencemarketresearch.com
TABLE OF CONTENTS 1. Introduction 1.1. Report Description 1.2. Market Segmentation 1.3. Research Methodology 1.4. List of Abbreviations 2. Executive Summary 3. Market Overview 3.1. Market Definition 3.2. Market Scope 3.3. Market Drivers 3.4. Market Restraints 3.5. Market Opportunities and Trends 3.6. Porter’s five force analysis 3.7. SWOT Analysis 3.8. PEST Analysis 3.9. Patent Analysis 3.10.
Impact of COVID 19 on Global Parkinson’s Disease Treatment Market
4. Parkinson’s Disease Treatment Market, By Drug Class, Market Size, Consumption and Forecast 2016 -2026 (USD Billion) 4.1. Global Parkinson’s Disease Treatment Market By Drug Class, 2016 -2026 (USD Billion) 4.1.1.Global Parkinson’s Disease Treatment Market By Carbidopa/Levodopa 4.1.2.Global Parkinson’s Disease Treatment Market By Catechol-O-methyl transferase (COMT) inhibitors 4.1.3.Global Parkinson’s Disease Treatment Market By Dopamine agonists (non-ergoline) 4.1.4.Global Parkinson’s Disease Treatment Market By Dopamine precursors 4.1.5.Global Parkinson’s Disease Treatment Market By Monoamine oxidase B inhibitors (MAO-B inhibitors) 4.1.6.Global Parkinson’s Disease Treatment Market By Others 4.2. Global Parkinson’s Disease Treatment Market By Drug Class Share, 2016 -2026 (%) 5. Parkinson’s Disease Treatment Market, By Patient Care Setting, Market Size, Consumption and Forecast 2016 -2026 (USD Billion) 5.1. Global Parkinson’s Disease Treatment Market By Patient Care Setting, 2016 -2026 (USD Billion) Transilience Market Research | Sales@transiliencemarketresearch.com
7
5.1.1.Global Parkinson’s Disease Treatment Market By Clinics 5.1.2.Global Parkinson’s Disease Treatment Market By Hospitals 5.2. Global Parkinson’s Disease Treatment Market By Patient Care Setting Share, 2016 -2026 (%) 6. Parkinson’s Disease Treatment Market, By Medical Devices, Market Size, Consumption and Forecast 2016 -2026 (USD Billion) 6.1. Global Parkinson’s Disease Treatment Market By Medical Devices, 2016 -2026 (USD Billion) 6.1.1.Global Parkinson’s Disease Treatment Market By Deep Brain Stimulation (DBS) Devices 6.1.2.Global Parkinson’s Disease Treatment Market By Levodopa Enteral Suspension delivery devices 6.2. Global Parkinson’s Disease Treatment Market By Medical Devices Share, 2016 -2026 (%) 7. Parkinson’s Disease Treatment Market, By Distribution Channel, Market Size, Consumption and Forecast 2016 -2026 (USD Billion) 7.1. Global Parkinson’s Disease Treatment Market By Distribution Channel, 2016 -2026 (USD Billion) 7.1.1.Global Parkinson’s Disease Treatment Market By Online pharmacies 7.1.2.Global Parkinson’s Disease Treatment Market By Retail pharmacies 7.1.3.Global Parkinson’s Disease Treatment Market By Hospital pharmacies 7.2. Global Parkinson’s Disease Treatment Market By Distribution Channel Share, 2016 -2026 (%) 8. Parkinson’s Disease Treatment Market, By Region Market Size, Consumption and Forecast 2016 -2026 8.1. NORTH AMERICA 8.1.1.Key Findings 8.1.2.Impact of COVID 19 8.1.3.Key market trends, growth factors and opportunities 8.1.4.North America Parkinson’s Disease Treatment Market by Country 2016 -2026 (USD Billion) 8.1.5.North America Parkinson’s Disease Treatment Market By Drug Class 2016 -2026 (USD Billion) 8.1.6.North America Parkinson’s Disease Treatment Market By Medical Devices 2016 -2026 (USD Billion) 8.1.7.North America Parkinson’s Disease Treatment Market By Patient Care Setting 2016 2026 (USD Billion)
Transilience Market Research | Sales@transiliencemarketresearch.com
8
8.1.8.North America Parkinson’s Disease Treatment Market By Distribution Channel 2016 2026 (USD Billion) 8.2. EUROPE 8.2.1.Key Findings 8.2.2.Impact of COVID 19 8.2.3.Key market trends, growth factors and opportunities 8.2.4.Europe Parkinson’s Disease Treatment Market by Country 2016 -2026 (USD Billion) 8.2.5.Europe Parkinson’s Disease Treatment Market By Drug Class 2016 -2026 (USD Billion) 8.2.6.Europe Parkinson’s Disease Treatment Market By Medical Devices 2016 -2026 (USD Billion) 8.2.7.Europe Parkinson’s Disease Treatment Market By Patient Care Setting 2016 -2026 (USD Billion) 8.2.8.Europe Parkinson’s Disease Treatment Market By Distribution Channel 2016 -2026 (USD Billion) 8.3. ASIA PACIFIC 8.3.1.Key Findings 8.3.2.Impact of COVID 19 8.3.3.Key market trends, growth factors and opportunities 8.3.4.Asia Pacific Parkinson’s Disease Treatment Market by Country 2016 -2026 (USD Billion) 8.3.5.Asia Pacific Parkinson’s Disease Treatment Market By Drug Class 2016 -2026 (USD Billion) 8.3.6.Asia Pacific Parkinson’s Disease Treatment Market By Medical Devices 2016 -2026 (USD Billion) 8.3.7.Asia Pacific Parkinson’s Disease Treatment Market By Patient Care Setting 2016 -2026 (USD Billion) 8.3.8.Asia Pacific Parkinson’s Disease Treatment Market By Distribution Channel 2016 -2026 (USD Billion) 8.4. LATIN AMERICA 8.4.1.Key Findings 8.4.2.Impact of COVID 19 8.4.3.Key market trends, growth factors and opportunities 8.4.4.Latin America Parkinson’s Disease Treatment Market by Country 2016 -2026 (USD Billion)
Transilience Market Research | Sales@transiliencemarketresearch.com
9
8.4.5.Latin America Parkinson’s Disease Treatment Market By Drug Class 2016 -2026 (USD Billion) 8.4.6.Latin America Parkinson’s Disease Treatment Market By Medical Devices 2016 -2026 (USD Billion) 8.4.7.Latin America Parkinson’s Disease Treatment Market By Patient Care Setting 2016 2026 (USD Billion) 8.4.8.Latin America Parkinson’s Disease Treatment Market By Distribution Channel 2016 2026 (USD Billion) 8.5. MIDDLE EAST AND AFRICA 8.5.1.Key Findings 8.5.2.Impact of COVID 19 8.5.3.Key market trends, growth factors and opportunities 8.5.4.Middle East and Africa Parkinson’s Disease Treatment Market by Country 2016 -2026 (USD Billion) 8.5.5.Middle East and Africa Parkinson’s Disease Treatment Market By Drug Class 2016 2026 (USD Billion) 8.5.6.Middle East and Africa Parkinson’s Disease Treatment Market By Medical Devices 2016 -2026 (USD Billion) 8.5.7.Middle East and Africa Parkinson’s Disease Treatment Market By Patient Care Setting 2016 -2026 (USD Billion) 8.5.8.Middle East and Africa Parkinson’s Disease Treatment Market By Distribution Channel 2016 -2026 (USD Billion) 9. Competitive Landscape Analysis 9.1. Global Parkinson’s Disease Treatment Market Company Revenue, (USD Billion), 2016-2019 9.2. Global Parkinson’s Disease Treatment Market Company Share, (%), 2016-2019 10. Global Parkinson’s Disease Treatment Market Price Analysis 10.1.
Global Parkinson’s Disease Treatment Market Price By Regions
11. Global Parkinson’s Disease Treatment Market Value Chain Analysis 12. Company Profiles 12.1. 12.2. 12.3. 12.4. 12.5. 12.6. 12.7.
Apotex Inc. BIAL Pharm Cipla Inc. Daiichi Sankyo GlaxoSmithKline Plc. Impax Laboratories, Inc. Mylan N.V. Transilience Market Research | Sales@transiliencemarketresearch.com
10
12.8. 12.9. 12.10. 12.11. 12.12. 12.13. 12.14.
Novartis AG Orion Corporation Par Pharmaceutical Salix Pharmaceuticals Teva Pharmaceutical Industries Ltd. Wockhardt Limited Others
13. Appendix 14. List of Tables 15. List of Figures
11
Transilience Market Research | Sales@transiliencemarketresearch.com
Declaimer
In response to request/orders received, Transilience Analytics provides strategic business/market analysis services to a select group of customers that are limited to publications containing valuable market information. The publication is solely for our customers’ internal use. It is acknowledged by our customer, by placing the order that no part of this strategic market analysis service is for general publication or disclosure to third party. Transilience Analytics doesn’t make any warranty for the accuracy of the data as these are primarily based on interviews and therefore, liable for fluctuation. Also, Transilience Analytics doesn’t take responsibility for incorrect information supplied by manufacturers or users. Any resale, lending, disclosure or reproduction of this publication can only be made with prior written permission from Transilience Analytics. Transmission and/or reproduction of this document by any means or in any form (includes photocopying, mechanical, electronic, recording or otherwise) are prohibited without the permission of Transilience Analytics.
12
Transilience Market Research | Sales@transiliencemarketresearch.com
About Transilience Market Research
Transilience Market Research is a one stop industry provider of actionable and timely intelligence. We publish exclusive market research reports for more than 10 industry verticals. Since our inception our mission is to deliver cost effective reliable resources to back clients in decision-making processes and business development strategies. Providing B2B research to Fortune 500 companies and consulting research services. We are committed to deliver sustainable, profitable growth through in depth market research solutions.
Contact: +91-9404545879|Email us at sales@transiliencemarketresearch.com
Follow us on:
13
Transilience Market Research | Sales@transiliencemarketresearch.com